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Abstract 
Objective: Bilateral risk-reducing salpingo-oophorectomy (RRSO) has been shown to 
significantly reduce the risk of ovarian cancer.  This study assessed factors predicting 
uptake of RRSO.   
Methods/materials: Women participating in a large multiple-case breast cancer 
family cohort study who were at increased risk for ovarian and fallopian tube cancer 
(i.e. BRCA1 or BRCA2 mutation carrier or family history including at least one first- 
or second-degree relative with ovarian or fallopian tube cancer), with no personal 
history of cancer and with at least one ovary in situ at cohort enrolment, were eligible 
for this study.  Women who knew they did not carry the BRCA1 or BRCA2 mutation 
segregating in their family (true negatives) were excluded.  Sociodemographic, 
biological and psychosocial factors, including cancer-specific anxiety, perceived 
ovarian cancer risk, optimism and social support, were assessed using self-
administered questionnaires and interviews at cohort enrolment. RRSO uptake was 
self-reported every three years during systematic follow-up.     
Results: Of 2,859 women, 571 were eligible.  Mean age was 43.3 years; 62 women 
(10.9%) had RRSO a median of two years after cohort entry.  Factors predicting 
RRSO were: being parous (OR 3.3, p=0.015); knowing one’s mutation positive status 
(OR 2.9, p<0.001) and having a mother and/or sister who died from ovarian cancer 
(OR 2.5, p=0.013).  Psychological variables measured at cohort entry were not 
associated with RRSO. 
Discussion: These results suggest that women at high risk for ovarian cancer make 
decisions about RRSO based on risk and individual socio-demographic 
characteristics, rather than in response to psychological factors such as anxiety. 
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Introduction 
 
Hereditary breast/ovarian cancer (HBOC) syndrome describes the occurrence of 
breast cancer and ovarian and related gynecologic cancers in multiple family members 
across several generations. In about 20-30% of families this is due to a germline 
mutation in the BRCA1 or BRCA2 gene.  The lifetime risks for ovarian and related 
gynecologic cancers range from 40% to 60% for carriers of BRCA1 mutations and 
10% to 20% for carriers of BRCA2 mutations [1].  Bilateral risk-reducing salpingo-
oophorectomy (RRSO) has been shown to significantly reduce the risk of ovarian and 
related gynecologic cancers (hazard ratio of 0.21, 95% CI=0.12 to 0.39) [2], and to 
approximately halve breast cancer risk if undertaken in pre-menopausal women. Due 
to the lack of efficacy of screening [3] and the high mortality associated with ovarian 
and related gynecologic cancers, RRSO is currently considered the optimal risk 
management strategy for women at high risk [2].   
It is now recognized that fallopian tube and primary peritoneal carcinomas are 
histologically and clinically identical to invasive serous epithelial ovarian cancer and 
have a common embryological origin, with most now considered to be derived from 
the fimbria of the fallopian tubes [4]. However for the sake of brevity, this group of 
cancers will be referred to as ‘ovarian cancer’ hereafter, although arguably the term 
‘ovarian cancer’ is misleading and the best terminology is being debated at present. 
A growing body of data has become available on the patient and family history 
characteristics that predict uptake of RRSO.  These include being older, e.g. [5, 6], 
number of children e.g. [6], having a family history of ovarian cancer, e.g. [6, 7], or a 
personal history of breast cancer, e.g. [8], and being a carrier of a BRCA1 or BRCA2 
mutation, e.g. [7, 9].   However, almost no empirical evidence is available on the 
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psychological determinants of the decision to undertake RRSO.  Cognitive and 
affective factors, as well as personal values, are likely to be as important as, if not 
more important than, the individual woman’s actual ovarian cancer risk, as reflected 
by factors such as age, strength of family history, and carrier status.  For example, 
dispositional optimism may be considered a dimension potentially underlying 
decisions about RRSO; according to the framework developed by Scheier and Carver 
[10], optimism is thought to have important behavioral consequences, which derive 
from a generalized expectancy that good things will happen.  
This study fills a gap in the existing literature by assessing the psychological 
factors associated with uptake of RRSO in a cohort of women at increased risk for 
ovarian cancer.  In accordance with the framework developed by Scheier and Carver 
[10], we hypothesize that women who are more optimistic, will be less inclined to opt 
for RRSO.  We also hypothesize that women with more social support will be more 
likely to take up RRSO, consistent with literature showing the strong documented role 
of social support in promoting positive psychological adjustment [11] and potentially 
women’s ability to implement their decisions about risk management [11].  
Furthermore, corresponding to the related literature that explores determinants of 
uptake of risk-reducing surgery in women at increased risk for breast/ovarian cancer, 
it is hypothesized that uptake of RRSO will be associated with perceived risk for 
ovarian cancer [12] and/or breast/ovarian-cancer related anxiety [13] and that these 
associations may be modified by age, given that recommendations for RRSO are age-
specific [3]. 
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Materials and Methods 
 
The Sample 
 
This study was approved by all the required Institutional Review Boards.  The sample 
for this study was drawn from women participating in two prospective sub-studies 
(the Clinical Follow-up study and the Psychosocial study [14]) of a large genetic, 
epidemiological, medical and clinical data resource of individuals from multiple-case 
breast cancer families across Australia and New Zealand (the Kathleen Cuningham 
Foundation Consortium for Research into Familial Breast Cancer - kConFab). 
kConFab is a cohort of  multiple-case breast cancer families from Australia and New 
Zealand [15]. Families are recruited after an initial family member attends a 
consultation in one of 16 family cancer clinics. Eligibility criteria for families are 
complex, but include a strong family history of breast cancer and/or ovarian cancer, or 
a documented BRCA1 or BRCA2 mutation [15].  
Blood is drawn for potential mutation analysis at the time of enrolment 
(although only key individuals in each family are actually tested) and an 
epidemiology and family history questionnaire is completed. Unless the individual has 
attended a familial cancer clinic, genetic counseling does not take place prior to any 
research-based genetic testing. When a BRCA1 or BRCA2 mutation is found in a 
family member, all enrolled family members who had previously indicated they 
would like to receive such information are notified by letter that relevant genetic 
information has become available and that they now have the option of attending a 
familial cancer clinic for genetic counseling and clinical genetic testing for the family 
mutation. 
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Clinical follow-up data and psychosocial data are collected in parallel using 
three-yearly self-report questionnaires and a semi-structured interview [14]. All 
participants provided informed consent at cohort enrolment.   Cancer events, risk 
management practices, epidemiological and lifestyle risk factors, cancer risk 
perception, psychological variables, personality characteristics, levels of social 
support and life-event stress are updated every three years.  
To be eligible for the current analysis, women had to be ‘unaffected’ with 
cancer at the time of cohort enrolment (i.e. no personal history of cancer, except non-
melanoma skin cancer or cervical intraepithelial neoplasia CIN I-III), have at least one 
ovary in situ at the time of cohort enrolment, be at increased risk for ovarian cancer 
(i.e. carry a BRCA1 or BRCA2 mutation and/or have at least one first- or second-
degree relative with ovarian cancer).  Women who were found to be ‘true negatives’ 
(i.e. proven non-carriers of the BRCA1 or BRCA2 mutation segregating in their 
family) and knew their mutation status were excluded from the analyses, as were 
women who developed ovarian cancer after cohort enrolment. Women who developed 
breast and cancers other than ovarian cancer after cohort enrolment were included in 
the analysis.   
 
Measures 
 
Predictor variables 
 All predictor variables were assessed at cohort entry. 
Demographic variables: Data on age, educational level, marital status and 
parity were collected at interview.   
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Family history variables: The following family history data were included in 
the analysis: data on total number of first- and second-degree relatives diagnosed with 
ovarian cancer, and whether the woman’s mother or (at least one of) her sister/s died 
from ovarian cancer.   
Genetic testing results: Actual BRCA1 and BRCA2 mutation status was based 
on kConFab records rather than self-report.  Participants’ knowledge of their mutation 
status was determined during the psychosocial interview.  Data on whether a woman 
had attended a familial cancer clinic were collected as part of the Clinical Follow-Up 
study.  
Perceived lifetime risk of developing ovarian cancer: Perceived lifetime risk 
of developing ovarian cancer was assessed by asking participants to indicate their 
perceived risk on a numerical differential scale ranging from 0 (‘No chance’) to 100 
(‘Definitely’).  
Actual lifetime risk of developing ovarian cancer: Actual lifetime risk of 
developing ovarian cancer was calculated using the Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation Algorithm (BOADICEA), which can be 
used to estimate the risks of developing ovarian cancer by age 70 [16]. 
Cancer-specific anxiety: This was assessed using the seven-item Intrusive 
Thoughts subscale of the Impact of Event Scale (IES) [17]. Intrusion is defined as ‘the 
involuntary entry into awareness of ideas, memories and emotions.’ Specifically, 
participants were asked about the frequency and severity of intrusive thoughts about 
being at risk of developing breast/ovarian cancer in the past week, ranging from ‘Not 
at all’ to ‘Often’. Scores range from 0-35, with higher scores indicating more intrusive 
thoughts.  
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Life Orientation Test (LOT): The LOT was included to assess dispositional 
optimism.  It is a widely used questionnaire with well-documented psychometric 
properties [10]. Scores range from 0 to 32, with higher scores indicating more 
optimism.   
Social support: This was assessed by the Duke-UNC Functional Social 
Support Questionnaire [11]. This 8-item scale is a validated measure of the degree of 
satisfaction with available support.  Scores range from 8 to 40, with higher scores 
indicating more social support. 
 
Outcome variable 
Uptake of risk-reducing salpingo-oophorectomy (RRSO): Data on uptake of 
RRSO during the follow-up period was taken from the most recent three-yearly 
Clinical Follow-Up study questionnaire, which was administered at least three years 
and, in some cases, up to nine years after baseline assessment, depending on time 
passed since cohort entry.     
 
Statistical analysis 
 
Data were initially explored for normality of distribution.  Bivariate analyses were 
used to assess the associations between predictor variables and uptake of RRSO.  
None of the continuous variables were normally distributed, and thus Mann Whitney 
U tests were used in the bivariate analysis of these variables.  Categorical variables 
were assessed using Pearson chi-square analyses.  For multivariate analyses, all 
variables with p<0.25 in bivariate analyses were entered into a logistic regression and 
then removed progressively using a backward elimination modeling strategy [18], 
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until only those variables with p<0.05 remained, while adjusting for age as a potential 
confounding variable.  The Hosmer-Lemeshow goodness of fit test was performed 
and confirmed the appropriateness of tests. 
Analyses were also conducted to ascertain whether breast/ovarian cancer-
specific anxiety and/or perceived ovarian cancer risk were associated with uptake of 
RRSO depending on age group (<40 years, 40-49, versus 50+).  The corresponding 
interaction terms were entered (psychological variable by age group), one by one, into 
the final model.  However, none of the interaction terms were significant, and they 
were, therefore, omitted from the final model.   Furthermore, potential interactions 
between mutation status and a range of demographic, family history and 
psychological variables (age, parity, total number of first- and second-degree relatives 
with ovarian cancer, perceived ovarian cancer risk, and cancer-specific anxiety) were 
assessed but found not to be significant.   
Our sample size of 571 women  provided 80% power at a 0.05 level of 
significance to detect a difference of 10% in perceived ovarian cancer lifetime risk 
between women who had an RRSO (N=62) and those who did not (N=509) did not, 
based on  SD=29.5 and 25.7 respectively, range 0 to 100).  This difference 
corresponds to an effect size difference of 0.4, that is a medium effect size [19].  This 
difference is based on the smallest effect that would have clear public health 
significance and provides a sensitive indicator of clinically meaningful differences 
[20]. 
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Results 
 
Of the entire sample of 2,859 unaffected women included in the kConFab 
Psychosocial and Clinical Follow-Up study, 805 (28.2%) women were at increased 
risk for ovarian cancer according to the eligibility criteria for inclusion in the analysis 
stated above.  Of these 805 women, 195 women (23.9%) at increased risk for ovarian 
cancer had undergone RRSO, 133 (16.3%) had undergone RRSO prior to cohort entry 
and were therefore not eligible for inclusion in this analysis, and 62 women (7.6%) 
after cohort entry.           
The final sample for this prospective analysis consisted of 571 women, who 
met all the eligibility criteria for this current analysis.  See Figure 1 for a description 
of how the final sample size was established.   Table 1 describes the characteristics of 
the sample at baseline.  The mean age of the sample was 43.3 years (SD 12.8). 
Seventy-four percent of women were parous.  The number of first- and second-degree 
relatives diagnosed with ovarian cancer ranged from 0 to 12 (median of 1).  One 
hundred and nineteen women (24.6%) reported having been tested and knowing that 
they were mutation positive, while 452 (75.4%) reported not having been tested or 
being ineligible for testing because no family-specific mutation had been identified to 
enable them to have predictive genetic testing.  The mean actual life time risk of 
developing ovarian cancer according to BOADICEA was 9.1%.  Forty-nine percent 
(49.2%) of women reported having attended a familial cancer clinic.   
Of the 571 women included in this prospective analysis, 62 (10.9%) reported 
having RRSO during the follow-up period, a median of two years (range: one month 
to eight years) following the completion of baseline psychosocial questionnaires.    
Amongst women included in the prospective analysis, 23 (15.6%) underwent RRSO 
 13 
before age 40, compared to 21 (13.7%) between ages 40 and 49 years, and 18 (19.8%) 
after the age of 49 years; uptake was not statistically different between age groups.  
The mean age of women who underwent RRSO was 43.8 (SD 9.0) and that of those 
who did not was 43.2 (SD 13.3).    
 
[Insert Figure 1 about here] 
 [Insert Table 1 about here] 
 
Tables 2 and 3 show the results of bivariate analyses of the categorical and 
continuous variables respectively, hypothesized to be potentially associated with 
RRSO. Women who were married or living as married were significantly more likely 
to have had RRSO, compared to those who were not married (13.0% versus 6.0%, 
χ2=5.33, p=0.021).  Similarly, those with offspring were significantly more likely to 
have undergone RRSO, compared to those without offspring (13.1% versus 4.7%, 
χ2=7.95, p=0.005).  Furthermore, women who had been tested and informed of their 
mutation positive result were more likely to have undergone RRSO compared to those 
who had not been tested or who had been tested but not been informed of the result 
(20.2% versus 8.7%, χ2=11.44, p<0.001).  Finally, women who had a mother or 
sister(s) who had died from ovarian cancer were more likely to have opted for RRSO 
than those who had not (17.2% versus 9.7%, χ2=4.32, p=0.038).  None of the 
psychological variables were associated with uptake of RRSO nor was actual ovarian 
cancer risk as assessed by BOADICEA. 
 
[Insert Tables 2 and 3 about here] 
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Table 4 describes the final logistic regression model, which shows that women 
who had offspring (OR 3.26, 95% CI 1.25, 8.48, p=0.015), knew that they were 
mutation positive (OR 2.87, 95% CI 1.53, 5.39, p<0.001), and/or had a mother and/or 
sister who died from ovarian cancer (OR 2.49, 95% CI 1.21, 5.15, p=0.013), were 
more likely to have had an RRSO, having adjusted for age as a potential confounder 
(p=0.68).  Relationship status was no longer significantly associated with RRSO in 
multivariate analyses.   
 
[Insert Table 4 about here] 
 
Discussion 
 
A growing body of literature has become available on the socio-demographic and 
family history factors predicting uptake of RRSO [21].  However, surprisingly few 
studies have incorporated an assessment of women’s psychological characteristics as 
potential determinants of decision-making about RRSO.  Findings from this small 
number of studies are somewhat conflicting [6, 12, 22, 23] in terms of the correlates 
and/or predictors of intention to have, and actual uptake of RRSO.  With the 
exception of one study, which reports on attitudes to, as opposed to actual uptake of, 
RRSO in the kConFab cohort [23], all of these previous studies involved women 
recruited through specialist familial cancer clinics or gynecological clinics.  Women 
attending such clinics are self-selected and may be motivated to attend clinics to 
discuss risk-reducing surgery by high levels of anxiety or perceived risk [23].  By 
contrast, our study relates to a more broadly recruited cohort of women at high risk 
for breast/ovarian cancer, half of whom have never attended a familial cancer clinic.  
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Thus, the findings reported are more likely to be representative of the psychological 
responses of the larger population of women at increased risk for ovarian cancer. 
Previous research shows that women opting for risk-reducing surgery may be 
motivated by high levels of anxiety about breast/ovarian cancer [6, 24] and/or high 
levels of perceived risk [12, 22, 23]. The results reported here do not support this 
previous research.  The results reported here suggest that among women in the 
kConFab cohort decision-making about RRSO is associated with socio-demographic 
characteristics and knowledge about carrier status, rather than psychological factors 
such as high levels of anxiety and perceived risk.   
Our data also did not confirm our hypothesis of a positive association between 
social support and uptake of RRSO; although perhaps surprising, this findings is 
consistent with a recent study of women‘s decision-making regarding risk-reducing 
mastectomy, which highlights that many women felt that the decision was ultimately 
theirs to make despite the influence of friends, family, and the medical team [25].  
Our hypothesis of an association between optimism and uptake of RRSO was 
also not confirmed.   It has been argued that successful adaptation to cancer depends 
on the ability to sustain and modify illusions that buffer present and future threats 
[26].  Similarly, unrealistic optimism (also referred to as optimism bias) about 
perceived risk levels of threatening events can be adaptive [27].  However, it can be 
argued that optimism bias in the context of hereditary cancer is maladaptive, as it is 
likely to cause women to be less inclined to take up effective measures with proven 
ability to lower the risk of cancer developing in the future. 
Our findings demonstrate that women with offspring are more likely to opt for 
RRSO; this result is consistent with other studies, which found that not having 
children was associated with delaying surgery [9, 28].    The observed association 
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between having offspring and uptake of RRSO is of course not surprising, given that 
RRSO results in irreversible infertility, and is therefore unlikely to be attractive to 
women who have not yet had children or those who are parous but are uncertain about 
whether to have more children.  Furthermore, clinical practice guidelines recommend 
that RRSO is used for women who have completed childbearing [3].  In contrast to 
previous studies, e.g. [5], increasing age was not associated with uptake of RRSO 
once parity had been adjusted for in multivariate regression, suggesting that, amongst 
pre-menopausal women, childbearing plans rather than concerns about menopausal 
symptoms or sexual side-effects of RRSO may be more important determinants of 
decision-making about RRSO. 
We also found that proven carriers of a BRCA1 or BRCA2 mutation were more 
likely to undergo RRSO, underscoring similar findings reported elsewhere [7].  This 
result indicates that women may derive a sense of certainty from having their 
mutation status confirmed, and that women use such personally relevant information 
to make decisions about RRSO. 
Finally, we found that women who had a mother and/or sister who died from 
ovarian cancer were more likely to opt for RRSO, compared to those who had not.  
Thus experience of a mother’s and/or sister’s illness and ultimate death due to ovarian 
cancer may arouse strong fears and concerns about a woman’s own health and life 
expectancy, and such concerns in turn are likely to motivate women to opt for RRSO, 
given its proven effectiveness in reducing the risk of ovarian cancer.   
Interestingly, uptake of RRSO was not associated with actual risk of 
developing ovarian cancer, which may in part reflect the fact that about half the 
sample had never had their risk formally assessed at a familial cancer clinic.  On the 
other hand, our findings do correspond to previous findings in the area of 
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psychological aspects of genetic testing which show that psychological factors, rather 
than objective risk, guide interest in genetic testing and psychological adjustment to 
test results. For example, amongst individuals at risk of developing hereditary breast 
cancer or hereditary nonpolyposis colorectal cancer, interest in genetic testing is 
significantly associated with perceived risk but not objective risk [29], and adjustment 
to results has been found to depend more on pretest psychological adjustment than the 
test result itself [29]. 
The limitations of our study should be noted.  Our study did not assess 
physician recommendation for RRSO, which has been shown to be a key factor in 
determining cancer screening uptake [28] and is likely to also be important in 
influencing decisions about RRSO.  The relatively low RRSO uptake rate in our 
prospectively assessed sample (10.9%) needs to be considered in the context of this 
being a non-clinical cohort; almost 60% of the women have had no direct contact with 
a familial cancer clinic and have thus not necessarily received genetic counseling or 
specialist risk management advice.  Another shortcoming of our study is that 
psychological variables were assessed in some cases several years prior to RRSO, and 
these variables might have been different just prior to RRSO.    On the other hand, the 
long follow-up period also represents a strength of the study, given previous studies 
that show women often take many years to decide to have RRSO [6, 28].  We also 
acknowledge that our sample is heterogeneous given both women who knew they 
were mutation positive were included as well as those who did not know their 
mutation status.  On the other hand, the heterogeneity of the sample also represents a 
strength, in that it reflects current clinical practice, where mutation testing can be 
offered to a minority of women only and where most women have to make decisions 
about their ovarian cancer risk management within a context of uncertainty without 
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the benefit of having been provided with their mutation testing results to clarify their 
risk. Finally, it is unknown to what extent our findings on the predictors of uptake of 
RRSO are generalisable to other countries, given the evidence available on the 
substantial international differences in both attitudes to, and uptake of, RRSO [30].  
Such differences are likely to reflect differences in provider [31] and patient attitudes 
[32], which are at least in part culturally determined.   
These results suggest that women at high risk for ovarian cancer make 
decisions about RRSO based on risk and individual socio-demographic 
circumstances, rather than in response to psychological factors such as anxiety. 
 
Acknowledgments This study was funded by National Health and Medical Research 
Council (NHMRC) Project Grants No. 153824, 301930, 457316, 145684, 288704, 
and 454508 and by a National Breast Cancer Foundation and Cancer Australia 
Priority Driven Collaborative Cancer Research Grant (#628333).  kConFab is 
supported by grants from the National Breast Cancer Foundation, the NHMRC, the 
Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, 
Tasmania and South Australia, and the Cancer Foundation of Western Australia. 
Bettina Meiser receives a Career Development Award from the NHMRC.  Phyllis 
Butow receives a Principal Research Fellowship from NHMRC.  Kelly-Anne Phillips 
is the John Colebatch Clinical Research Fellow of the Cancer Council Victoria. We 
are very grateful to the many families who contribute to kConFab. We also wish to 
thank Lucy Stanhope, Kate Birch, Heather Thorne, Eveline Niedermayr, the kConFab 
research nurses and staff, and the heads and staff of the Family Cancer Clinics.   We 
also thank Dr Adrian Bickerstaff and John Hopper for using the Breast and Ovarian 
 19 
Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) to 
calculate actual ovarian cancer risk. 
 
Conflict of interest 
The authors have no conflicts of interest to declare. 
 
 
 
 20 
Fig. 1 Description of sample selection from complete psychosocial database 
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Table 1  Sociodemographic and family history characteristics (N=571)a 
Characteristics N (%) 
Age in years 
Mean 43.3, SD 12.8, range 18 to 74 years 
      <30 
     30-39 
     40-49 
     50-59 
     60-69 
     70+ 
 
 
76 (13.3) 
162 (28.4) 
153 (26.8) 
100 (17.5) 
63 (11.0) 
14 (3.0) 
Marital status  
      Married/living as married 
      Widowed/single/divorced 
 
404 (73.2) 
149 (26.8) 
Educational level       
      No university education        
      University graduate 
 
449 (79.6) 
115 (20.4) 
Country of birth 
      Australia 
      New Zealand 
      UK 
      Other  
 
464 (81.3) 
53 (9.3) 
27 (4.8) 
27 (4.8) 
 
Offspring  
      One or more offspring  
      No offspring  
 
421 (73.9) 
149 (26.1) 
Total number of FDR and SDR with OvCa 
       0  
       1 
       2 
       3+ 
 
110 (19.3) 
367 (64.3) 
70 (12.3) 
24 (4.3) 
Research genetic mutation status 
       BRCA1/2 mutation positive 
       BRCA1/2 mutation negativeb  
       No mutation identified in family    
 
177 (31.1) 
169 (29.6) 
224 (39.3) 
Knowledge of mutation status 
       Individual tested and informed mutation positive 
       Individual either  not tested or no mutation identified in family 
 
119 (24.6) 
452 (75.4) 
Mother or sister/s has died from OvCa 
       Yes 
       No 
 
87 (15.2) 
484 (84.8) 
OvCa ovarian cancer, FDR first-degree relatives, SDR second-degree relatives 
a Cell frequencies vary due to missing data for some variables 
b These women are true mutation negatives (according to the research genetic testing result) but have 
chosen not to have clinical testing, so they are unaware they are mutation negative 
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  Table 2  Bivariate analysis of categorical predictor variables related to uptake of RRSO (N=571) 
 
  RRSO risk-reducing salpingo-oophorectomy 
   a Cell frequencies vary due to missing data for some variables 
  χ2 Pearson chi-square value 
  * Entered into regression model 
 
 
 
Predictor variables Had RRSO  
(N=62) 
Did not have RRSO 
(N=509) 
  
 Na % Na % χ2 p 
Marital status 
       Married/living together  
       Not married/living together 
 
53 
9 
 
13.0 
6.0 
 
355 
140 
 
87.0 
94.0 
 
5.33 
 
0.021* 
Offspring 
       Has offspring 
       Does not have offspring 
 
55 
7 
 
13.1 
4.7 
 
366 
142 
 
86.9 
95.3 
 
7.95 
 
0.005* 
Education  
       Not a university graduate             
       University graduate 
 
 
51 
11 
 
11.4 
9.6 
 
398 
104 
 
 
88.6 
90.4 
 
0.30 
 
0.58 
Knowledge of mutation status 
       Individual tested and                     
            informed mutation positive 
       Individual either not tested or not  
             informed 
 
24 
 
31 
 
20.2 
 
8.7 
 
95 
 
325 
 
79.8 
 
91.3 
 
11.44 
 
<0.001* 
Family mortality history 
       Mother or sister died from   
              ovarian cancer 
       Mother or sister did not die from  
              ovarian cancer 
 
 
15 
 
47 
 
17.2 
 
9.7 
 
72 
 
437 
 
82.8 
 
90.3 
 
4.32 
 
0.038* 
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Table 3  Bivariate analysis of continuous predictor variables related to uptake of RRSO (N=571) 
 
Predictor variables Had RRSO (N=62) 
 
Did not have RRSO 
(N=509) 
  
 N Mean (SD)   N Mean (SD) z p 
Age 62 43.8 (9.0) 503 43.2 (13.3) -0.75 0.45 
Total no of FDRs and     
     SDRs with OvCa 
 
62 
 
1.4 (1.7) 
 
509 
 
1.2 (0.99) 
 
-0.05 
 
0.96 
Perceived ovarian   
      cancer risk 
 
61 
 
45.5 (29.5) 
 
503 
 
40.9 (25.7) 
 
-1.20 
 
0.23* 
Actual ovarian        
      cancer risk  
Cancer-specific   
      anxiety  
 
61 
 
60 
 
11.0 (14.5) 
 
6.3 (8.1) 
 
499 
 
508 
 
8.9 (13.4) 
 
7.1 (8.3) 
 
-1.28 
 
-0.80 
 
0.20* 
 
0.43 
Optimism 62 
 
20.0 (4.9) 507 
 
19.8 (5.7) -0.24 0.81 
Social support 62  
 
30.9 (7.3) 
 
508 
 
30.1 (7.8) 
 
-0.70 0.48 
 
RRSO risk-reducing salpingo-oophorectomy, FDR first-degree relative, SDR second-degree relative, 
OvCa ovarian cancer 
z Mann Whitney U value 
*Entered into regression model   
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Table 4 Final model of logistic regression predicting uptake of RRSO (N=571) 
 
Variable OR* 95% CI OR p 
    
Offspring  
     Yes 
     No 
 
3.26 
 
1.25, 8.48 
 
0.015 
Knowledge of mutation status 
     Individual tested and informed  mutation    
     positive  
     Individual not tested or not informed of result 
 
2.87 
 
1.53, 5.39 
 
<0.001 
Family mortality history 
       Mother or sister died from ovarian cancer 
       Mother or sister did not die from ovarian cancer 
 
2.49 
 
1.21, 5.15 
 
0.013 
Age** 0.99 0.97, 1.02 0.68 
OR odds ratios 
Note: Final model -2 Log likelihood 314.53, χ2= 20.59, p=0.009 
* Odds ratio refers to comparisons with the category listed last 
** Age was entered as a continuous variable 
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